Insight Molecular Diagnostics Inc. (iMDx), formerly known as Oncocyte Corporation, reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company generated net revenue of $260,000 for the third quarter, a substantial increase of 126% compared to $115,000 in the same period last year. For the nine months ended September 30, 2025, total revenue reached $2.9 million, up 638% from $395,000 in the prior year. Despite this revenue growth, iMDx reported a net loss of $10.9 million for the quarter, an improvement from a loss of $13.5 million in the previous year, and a net loss of $27.3 million for the nine-month period, slightly higher than the $27.2 million loss recorded in the same timeframe last year.
The company’s operational metrics indicate a strategic shift towards its transplant-related products, particularly the GraftAssureCore and GraftAssureIQ assays. iMDx has begun commercializing these products, with GraftAssureCore receiving positive coverage from MolDx and Medicare reimbursement rates established at $2,753 per result. The company also reported its first sales of GraftAssureIQ kits to research laboratories in May 2025. As of September 30, 2025, iMDx had $18.7 million in cash and cash equivalents, a significant increase from $8.6 million at the end of 2024, bolstered by a successful February 2025 offering that raised approximately $29.1 million.
In terms of operational changes, iMDx has expanded its workforce and facilities, moving its headquarters to Nashville, Tennessee, and establishing a research and development lab in Göttingen, Germany. The company’s employee headcount has increased, reflecting its commitment to enhancing its research and development capabilities. iMDx's strategic partnership with Bio-Rad Laboratories, initiated in April 2024, aims to develop and commercialize kitted transplant products, further solidifying its market position.
The filing also highlighted the company's ongoing challenges, including an accumulated deficit of $377.8 million as of September 30, 2025, and the need for continued capital to support its operations and product development. iMDx anticipates ongoing operating losses and negative cash flows in the near future, which may necessitate additional financing. The company is actively exploring various commercialization strategies, including partnerships and licensing agreements, to mitigate financial risks and enhance its market presence.
Looking ahead, iMDx remains focused on advancing its diagnostic tests for organ transplantation and oncology, with plans to submit for regulatory approvals for its products by the end of 2025. The company’s management believes that its innovative approach and strategic partnerships will drive future growth, although uncertainties in the market and regulatory landscape may impact its operational trajectory.
About Insight Molecular Diagnostics Inc.
Oncocyte Corporation develops molecular diagnostic tests for transplant rejection and cancer therapy response. Its core products include blood-based assays for organ damage detection and oncology biomarkers, serving hospitals, transplant centers, and research institutions. The company leverages proprietary technology, strategic partnerships, and intellectual property to enable decentralized testing, aiming to improve patient outcomes, reduce healthcare costs, and foster innovation in personalized medicine.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.